Halozyme Therapeutics | HALO - Net Income


Halozyme Therapeutics reported $150.05M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 3.64M 269.93M Mar/2026
Agios Pharmaceuticals USD -99.11M 8.93M Mar/2026
Alnylam Pharmaceuticals USD 205.99M 19.57M Mar/2026
Amarin USD -1.22M 6.51M Dec/2025
Amgen USD 1.82B 486M Mar/2026
Baxter International USD -15M 1.11B Mar/2026
Cara Therapeutics USD -5.53M 621K Sep/2025
Cytokinetics USD -206.03M 23M Mar/2026
DBV Technologies USD -33.16M 8.71M Sep/2025
Eli Lilly USD 7.4B 760M Mar/2026
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Halozyme Therapeutics USD 150.05M 291.64M Mar/2026
Ionis Pharmaceuticals USD -93M 136M Mar/2026
MannKind USD -15.95M 23.93M Dec/2025
Minerva Neurosciences USD 1.44M 21.07M Dec/2024
Nektar Therapeutics USD -36.08M 978K Dec/2025
Pfizer USD 2.69B 4.34B Mar/2026
Rigel Pharmaceuticals USD 12.42M 13.45M Sep/2024
United Therapeutics USD 274.9M 89.4M Mar/2026
Vanda Pharmaceuticals USD -18.9M 13.58M Dec/2024